# Rapport Therapeutics Inc. (RAPP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $45.77, market value $2.2 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Rapport Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 5.2×**. The shares trade at 5.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.4%** (5-yr avg -12.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -23.0%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 24.3%**. Earnings per share rose 24.3%.

## Financial health
- **Current ratio: 26.17** (quick 26.17). Current assets cover the next year's liabilities 26.17 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Rapport Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Rapport Therapeutics Inc.; the consensus is strong_buy, with an average price target of $62.05 (+36% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 198.2%** (YTD 50.9%, 3-mo 26.8%). The shares are up 198.2% over twelve months including dividends.
- **From 52-week high: -13.5%** (107.5% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.33** (volatility 134%). Beta of 1.33 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RAPP · Page: https://foliofundamentals.com/stocks/rapp

Not investment advice.